BioMarin Pharmaceutical SG&A Expenses 2010-2024 | BMRN
- BioMarin Pharmaceutical annual sg&a expenses for 2023 were $0.937B, a 9.75% increase from 2022.
- BioMarin Pharmaceutical annual sg&a expenses for 2022 were $0.854B, a 12.46% increase from 2021.
- BioMarin Pharmaceutical annual sg&a expenses for 2021 were $0.759B, a 2.94% increase from 2020.